FGF21 and metabolic dysfunction-associated steatotic liver disease: Our results demonstrated that FGF21 is more accurate for predicting the onset of simple steatosis, while CK18 including M30 and M65ED are better biomarkers for monitoring the prognosis of NAFLD patients.